Shigetaka Komori Chairman, Representative Director and CEO December 4, 2012 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management s current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors. Contents 1. Forecast for FY2013/3 2. Flat Panel Display Materials 3. Electronic Imaging (Digital Cameras) 4. Document 5. 6. Fujifilm s Potential 2
Forecast for FY2013/3 FY2012/3 FY2013/3 (forecast) (Billions of yen) Change from previous year Revenue 2,195.3 100.0% 2,210.0 100.0% 14.7 +0.7% Operating Income 112.9 5.1% 125.0 5.7% 12.1 +10.7% Income before Income Taxes 89.2 4.1% 105.0 4.8% 15.8 +17.7% Net Income Attributable to FUJIFILM Holdings 43.8 2.0% 45.0 2.0% 1.2 +2.8% Achieve the revenue/profit target by such measures as the launch of new products and thorough cost reductions throughout the Company 3 Flat Panel Display (FPD) Materials For TVs Sales volumes for TVs have been slackening in the rate of growth, due to the end of Japan s Eco-Point system and Chinese government policies for promoting the ownership of household electric products. On the other hand, screens for LCD panels have been expanding owing to such factors as increases in the size of TVs. TVs are still the main application for these screens. 114% 164% Small & Note PCs medium-sized items Monitors TVs FY2012/3 1H FY2013/3 1H FY2012/3 1H FY2013/3 1H VA film IPS film Index: total demand of FY2012/3 1H=100 Volume of panel shipments by application (as of FY2012/3, internal investigation) Further promote sales and a rise in the market share of VA/IPS film 4
Flat Panel Display (FPD) Materials For monitors & PCs Wide View film (WV film, Fujifilm holds a 100% market share) is mainly used for monitors. Demand for WV film remains weak, reflecting the weak demand overall for IT equipment, especially for monitors, caused by economic deterioration IPS VA No retardation film IPS WV WV No retardation film Monitors Note PCs (equipment usage rate for panels by retardation film, internal investigation) Promote sales for note PCs with low equipment usage rates and speedily develop WV film for such new applications as Ultrabook 5 Flat Panel Display (FPD) Materials For small and medium-sized applications Further growth is expected for small and medium-sized items (smartphones, tablet PCs, etc.) Raise market share for thin FUJITAC of 40μ (adoption by major client) Succeed in developing thin FUJITAC of 25μ and start mass-production within this fiscal year Promote development of thin-type retardation films 6
Flat Panel Display (FPD) Materials Profitability for the future Increase in the market share of retardation films, sales expansion of films for small and medium-sized items, and the development of WV film for new uses. Depreciation cost is declining, and the Company will maintain/raise sales and profit as a business that generates stable profit for the future 7 Electronic Imaging (Digital Cameras) Business strategies Worldwide demand for compact digital cameras has been dropping sharply, down approximately by 20% compared to the previous year. series Reinforce direct sales in emerging countries by establishing local subsidiaries Fujifilm s worldwide market share has increased Continue to focus on high-value-added models Expand lineup of high-performance interchangeable lenses Efficiently employ development/sales resources Thoroughly conduct cost reductions, including the review of model assortment. 8
Electronic Imaging (Digital Cameras) Premium interchangeable lens camera FUJIFILM X-E1 Premium compact digital camera FUJIFILM XF1 Continue to focus on high-value-added models Expand lineup of high-performance interchangeable lenses Efficiently employ development/sales resources Thoroughly conduct cost reductions, including the review of model assortment. 9 Document Growth strategies Anxiety over price competition and decline in demand Realize growth by offering solutions in document business, which has a wide definition, including electronic data, utilizing the Company s strong relationships with its clients that have been cultivated through direct sales Expand sales by launching strategic products for emerging countries Thoroughly conduct cost reductions Achieve operating margin of 10% in FY2014/3 10
Revenue ratios of consolidated subsidiaries Diosynth FUJIFILM Toyama Chemical Pharma New Drugs RI Pharma New Drugs Bio-Related Products Bio-Related Products Super Generics Present 感染症 放射性医薬品 ジェネリック Low-Molecular (Infectious Disease), Radiopharmaceuticals, Generics 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Establishment of business foundation Growth generated by new drugs and bio Great expansion 11 Establishment of pharmaceuticals business foundation (~2014) Secure profitability by reinforcing earning capacity of three consolidated subsidiaries (Toyama Chemical, FUJIFILM RI Pharma, FUJIFILM Diosynth Biotechnologies) In particular, expand business in the infectious disease field, mainly by Toyama Chemical FUJIFILM Diosynth Biotechnologies (UK), a contract manufacturing Radiopharmaceuticals organization for from FUJIFILM RI biopharmaceuticals Pharma Medicines for infectious disease from Toyama Chemical Make overall pharmaceuticals business profitable in FY2014/3 Focus on R&D of new drugs and on expansion of bio-related business, where great growth is expected in the future 12
Pipeline (example) FF-10501:Anticancer drug (myelodysplastic syndrome) A medicine for such rare diseases as myelodysplastic syndrome Planned to start PI in Jan. 2013 in Japan FF-10502:Anticancer drug (intractable solid cancer:pancreatic cancer/ovarian cancer, etc.) Expects higher response rate than existing drug (gemcitabine) Planned to start PI in 2014 FF-21101:Anticancer drug (intractable solid cancer:lung cancer/pancreatic cancer, etc.) Make a concentrated attack on cancer cells using β-ray s lethal ability, labeling radioisotope to antibody that accumulates around the cancerous part. Clinical research is planned to start from 2013, cooperating with a hospital in the United States. ITK-1:Anticancer drug (prostate cancer) A vaccine that treats cancer by reinforcing the patient s immunity Promote the development of distinctive new drugs by utilizing such technologies, cultivated through photographic films, as fine-chemical technologies, analysis technologies, synthesis technologies, and molecular designing technologies 13 Growth generated by new drugs and bio (2014~2019) Accelerate development especially in the cancer field, and launch new drugs Launch super generics using the Group s proprietary technologies Expand business in contract manufacturing organization (CMO) of biopharmaceuticals Great expansion (2019~) Greatly increase sales and profit by launching and expanding sales of distinctive new drugs in cancer field while reinforcing bio-related business, including CMO and biosimilars Develop to become the core business in the FUJIFILM Group 14
Fujifilm s s Potential Research and development FUJIFILM Advanced Research Laboratories Facilitate a dynamic fusion of extensive knowledge, technologies and techniques, in different areas Create differentiating technologies 15 Fujifilm s s Potential Develop new products by utilizing the Group s fundamental technologies Organic Material Technologies Analysis, Evaluation, and Simulation Technologies Inorganic Material Technologies Thin-Film Formulation and Processing Technologies Functional cosmetics 5 sec 20 sec Greatly improve penetration of Astaxanthin by applying such technologies as organic material technologies, nanotechnologies, and dispersion technologies Highly functional materials Develop transparent conductive film for such applications as touch panels, utilizing thin-film formulation and processing technologies, organic material technologies, and others Micro-needle array Promote the launch of microneedle arrays that deliver drugs into the body just by attaching them onto the skin, utilizing film manufacturing technologies and prescription processing technologies 16
Fujifilm s s Potential Synergies of Fujifilm and acquired companies Manufacturing technologies cultivated through photographic films Toyama Chemical Improve profitability Efficient manufacturing Decrease wastage factor Bedside and point-of-care ultrasound diagnostic equipment Sophisticated image processing technologies FUJIFILM Diosynth Biotechnologies Fujifilm SonoSite Differentiated products with high competitiveness Bedside and point-of-care ultrasound diagnostic equipment with high image quality and sturdiness 17 Fujifilm s s Potential Create products/businesses in healthcare, highly functional materials, and printing fields that other companies cannot imitate Realize continuous growth via unique and number one core technologies 18